March 12, 2020

FDA approval of Opdivo + Yervoy for patients with hepatocellular carcinoma (HCC)

Bristol Myers Squibb Company today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S.